Skip to content
Home / News |

Scancell Shares Surged 24.7% Today, Here’s Why

Scancell logo
Simon Mugo

Shares of Scancell Holdings Plc (LON: SCLP) today surged 24.7% after the company agreed to partner with Cobra Biologics to manufacture plasmid DNA required for use in its COVIDITY Phase 1 clinical trial for its COVID-19 vaccine in 2021.

Innovate UK is funding the project via a grant award to the consortium of Scancell, the University of Nottingham, and Trent University.

Today’s deal covers the good manufacturing practice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2.

X testing X
WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
5.0
Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

GMP production is a major breakthrough given that it makes it possible to manufacture vaccines at scale and to therapeutic-grade standards.

The second-generation COVID-19 vaccine is scheduled to start Phase 1 clinical trials in 2021.

“Our collaboration with Cobra is critical to us moving forward with our novel SARS-CoV-2 vaccine into the planned phase I clinical trial, COVIDITY,” said chief executive, Dr Cliff Holloway.

Adding:

“Cobra has the expertise needed to produce clinical-grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness and protection against COVID-19.”

Scancell Holdings share price

Tradingview chart of Scancell share price 02102020

Scancell shares today surged 24.7% to trade at 20.90p having ended Thursday’s session trading at 16.75p.

People who read this also read:

Simon Mugo
Simon Mugo
Contributor

Simon ist Autor und Analyst für den Bereich Finanzwesen und blickt auf über sechs Jahre professionelle Erfahrung als Trader zurück. Er absolvierte einen Bachelor in Mathematik und Informatik und hat eine Leidenschaft für die Finanzmärkte. Simon handelt FX, Rohstoffe und Aktien. Er konzentriert sich auf Price Action Trading.